What are the challenges in targeting β Catenin for cancer therapy?
One of the primary challenges in targeting β Catenin for cancer therapy is its dual role in cell-cell adhesion and transcriptional regulation. Inhibiting β Catenin’s function can disrupt normal cellular processes and lead to adverse effects. Additionally, the complexity of the Wnt/β-Catenin pathway and its involvement in multiple cellular functions make it difficult to design selective inhibitors that do not affect normal cells. Resistance to β Catenin inhibitors is another hurdle, necessitating the development of combination therapies to overcome this issue.
